Introducing TheraPHIX™ our thermostabilization breakthrough

RNAssist is proud to announce the development of TheraPHIX™, a pioneering solution for mRNA vaccine and therapeutic stability. In collaboration with the Centre for Process Innovation (CPI) and with funding from Innovate UK, we have successfully created a non-toxic, ambient temperature liquid-stable mRNA-LNP formulation that enhances both the RNA cargo and its lipid nanoparticle (LNP) vehicle.

Recent results from CPI highlight the effectiveness of TheraPHIX™. After 3 months of storage at 37°C in an external deep eutectic solvent (DES), mRNA retained 48% of its integrity, compared to complete degradation (0%) in a standard buffer solution under the same conditions. This breakthrough in RNA and LNP stability enables mRNA-LNPs to be stored and transported at ambient temperatures, dramatically reducing reliance on cold chain logistics, cutting costs, and lowering energy consumption.

TheraPHIX™ significantly extends the shelf life of mRNA vaccines and therapeutics, reducing wastage and increasing accessibility, particularly in low-income and remote regions. By stabilising both the RNA and the LNP, we ensure that nucleic acid therapeutics remain potent and effective, even in challenging storage environments.

Through integration into two distinct manufacturing workflows, TheraPHIX™ is making a direct impact on the production, storage, and transport of these critical medical supplies. Economically, it promises to lower storage and distribution costs, paving the way for improved vaccine availability and more effective disease control globally.

By addressing logistical challenges, TheraPHIX™ contributes to global health security, bridging healthcare gaps and ensuring equitable access to vaccines and therapeutics worldwide.

Want to learn more about our technology? Follow us on LinkedIn here: https://www.linkedin.com/company/rnassist/ or contact us here: https://rnassist.com/contact